Genelux Corp reports results for the quarter ended June 30 - Earnings Summary

• Genelux Corp GNLX.OQ reported a quarterly adjusted loss of 20 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -22 cents. The mean expectation of six analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -24 cents to -20 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Genelux Corp's reported EPS for the quarter was a loss of 20 cents​.

• The company reported a quarterly loss of $7.46 million.

• Genelux Corp shares had risen by 9.8% this quarter and gained 33.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Genelux Corp is $13.00, about 75.8% above its last closing price of $3.15

This summary was machine generated from LSEG data August 11 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)